Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice?
Weber
J J
JJ
Department of Pharmacy Services, Hermann Hospital (HH), Houston, TX 77030-1501, USA. Jeff_Weber@mhcs.org
Chong
K
K
D001157:Arterial Occlusive Diseases / Q000191:economics / Q000628:therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D010960:Plasminogen Activators / Q000191:economics / Q000627:therapeutic use*; D013300:Streptokinase / Q000191:economics / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000191:economics*; D014481:United States; D014568:Urokinase-Type Plasminogen Activator / Q000191:economics / Q000627:therapeutic use*
D013300:Streptokinase; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator